
The Danish biotech firm Genmab has lost a potential blockbuster drug. Genmab has decided to ditch the drug candidate enapotamab vedotin for treating cancer, which the firm announces in a statement.
"We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward," states CEO Jan van de Winkel in the press announcement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app